Agnostic investors or pure players in the MedTech sector: Who is becoming prominent in the early-stage financing scene?

Seed and Series A investments are critical to transforming new ideas into products and moving start-up teams into small businesses. From investors with a varied degree of specialisation to totally agnostic players only focusing on MedTech, who are the main players at these financing stages? What is the significance of the amount of earlystage investment today for cross-industry funds, specialised healthcare funds and pure players in the MedTech industry respectively?